期刊文献+

顺铂及拓扑替康对卵巢癌裸鼠移植瘤生长的抑制作用 被引量:2

Anticancer effects of cisplatin and topotecan on ovarian cancer in nude mice
暂未订购
导出
摘要 目的 :了解顺铂 (DDP)、拓扑替康 (TPT)单独及联合应用对卵巢癌裸鼠皮下移植瘤生长的抑制作用。方法 :裸鼠右侧背部皮下接种人卵巢癌SKOV3细胞 ,2 1d后分 4组治疗 ,每组 6只动物。对照组 ,腹腔注射无菌生理盐水 ;DDP组 ,腹腔注射DDP 3mg·kg-1 ;TPT组 ,腹腔注射TPT 5mg·kg-1 ;DDP +TPT组 ,腹腔注射DDP 3mg·kg-1 ,6h后腹腔注射TPT 5mg·kg-1 ;上述药物均每 4d注射 1次 ,共注射 4次 ,于实验第 39d处死裸鼠。治疗期间观察并记录各组裸鼠皮下移植瘤的生长情况 ,计算肿瘤体积、肿瘤生长抑制率 ,绘制肿瘤生长曲线。结果 :各治疗组治疗后肿瘤体积和抑瘤率与对照组相比差异均具有统计学意义 (P <0 .0 5 )。与DDP及TPT组比较 ,DDP +TPT联合用药组肿瘤体积明显减小 (P <0 .0 0 1 ) ,抑瘤率明显增高 (P <0 .0 0 1 )。结论 :DDP与TPT联合用药比 2药单独应用抑制肿瘤生长的作用更强 。 Aim: To evaluate the anticancer effects of cisplatin,topotecan, and cisplatin with topotecan to human ovarian epithelial cancer in nude mice. Methods: Twenty four nude mice were subcutaneously implanted with human ovarian epithelial cancer cell line SKOV3 on the right side of nude mice's back, and divided into 4 groups after 21 days:control group, cisplatin group, topotecan group,and cisplatin with topotecan group.Different treatments were served from 21st day after implantation and all mice were sacrificed after 39 days. The tumor volumes of the mice were measured respectively during the therapy time.The tumor growth inhibiting rates of each group were calculated. Moreover, the curves of tumor growth were drew. Results:Significant differences in average tumor volumes and tumor growth inhibition rates were found between the treatment group and the control group( P <0.05).The tumor volumes in combination group were significantly less than those of other groups( P <0.001). Compared with cisplatin group(26.54±8.42)% and topotecan group (38.18±11.12)%,the growth inhibiting rates of tumor in combination group (73.17±30.78)% were significantly higher. Conclusion: Combined application of cisplatin and topotecan has stronger inhibition on tumor growth than single use,and they has a synergic anticancer effect to ovarian cancer.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2004年第4期563-565,共3页 Journal of Zhengzhou University(Medical Sciences)
基金 河南省医学科技创新人才工程项目 2 0 0 3 0 2 7
关键词 卵巢肿瘤 裸鼠 顺铂 拓扑替康 ovarian carcivoma nude mice cisplatin, topotecan
  • 相关文献

参考文献7

  • 1Ozols RF. Update on the management of ovarian cancer. Cancer J, 2002, 8(suppl 1):S22
  • 2Holloway RW, Mehta RS, Finkler NJ, et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol, 2002,87(1): 8
  • 3Burris H, Kahn J, Johnson R, et al. SKF104864 preclinical studies of a new topisomerase I inhibitor . Proc Am Assc Cancer Res, 1990, 31:431
  • 4Herzog T J. Clinical experience with topotecan in relapsed ovarian cancer. Gynecol Oncol, 2003, 90(3 Pt 2):S3
  • 5Gore M, ten Bokkel Huinink W,Carmichael J,et al.Clinical evidence for topotecan paclitaxel non-cross-resistance in ovarian cancer.J Clin Oncol, 2001 ,19(7): 1 893
  • 6Romanelli S, Perego P, Pratesi G, et al. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems. Cancer Chemother Pharmacol, 1998, 41(5): 385
  • 7Speyer J, Hochster H, Wadler S, et al. Effective first line therapy of ovarian cancer(oc with cisplatin and prolonged topotecan infusion. A NYGOG/ECOG study. Proc Am Soc Clin Oncol, 2000,19:380a

同被引文献22

  • 1王惠兰,张贺玲,袁芳,黄向华,杨素娟.大蒜油单独及与顺铂联合对人宫颈癌Hela细胞生长影响的研究[J].实用妇产科杂志,2004,20(6):349-350. 被引量:8
  • 2孙传政,陈福进,曾木圣,李晓江,宋立兵,李满枝,曾宗渊,陈艳峰,隋军.多西他赛单用或与顺铂联合对舌鳞癌增殖的抑制作用[J].实用癌症杂志,2006,21(5):453-457. 被引量:3
  • 3范岚,谢海棠,周宏灏.中西药合用治疗肿瘤的相互作用及其机制探讨[J].中国临床药理学与治疗学,2007,12(2):134-139. 被引量:10
  • 4连丽娟.林巧稚妇科肿瘤学[M].4版.北京:人民卫生出版社,2006:356-365.
  • 5ARBYN M, CASTELLSAGUIE X, SANJOSIE S, et al. World- wide burden of cervical cancer in 2008 [ C ]. Ann Oncol, 2011, Apr 6.
  • 6ROSE P G, ALl S, WATKINS E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer:a Gynecologic Oncology Group Study[J]. J Clin 0ncol,2007,25 (9) :2804-2810.
  • 7DRISCOLL J J, MINTER A, DRISCOLL D A, et al. The ubiquitin-proteasome protein degradation pathway as a therapeutic strategy in the treatment of solid tumor malignancies[ J]. Anticancer Agents Med Chem, 2011,11 (2) :242-246.
  • 8DRISCOLL J J, DECHOWDHURY R. Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy [ J ]. Target Oncol, 2010, 5(4) :281-289.
  • 9HOUGARDY B M, MADURO J H, van der ZEE A G, et al. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis[ J]. Int J Cancer,2006,118 ( 8 ) : 1892-1900.
  • 10WANG J, SAMPATH A, RAYCHAUDHURI P, et al. Both Rb and E7 are regulated by the ubiquitin proteasome pathway in HPV- containing cervical tumor [ J ]. Cells, 2001,20 (34) : 740-749. .

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部